Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Tanner Johanns

Hematology | Oncology
Washington University
11133 Dunn Rd, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Embryonal Tumor with Multilayered Rosettes
Washington University
11133 Dunn Rd, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tanner Johanns is a Hematologist and an Oncologist in Saint Louis, Missouri. Dr. Johanns is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 51 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
11133 Dunn Rd, Saint Louis, MO 63136
Other Locations
WASHINGTON UNIVERSITY
10 Barnes W Dr, 200 Asthma And Allergy Cente, St Louis, MO 63141
WASHINGTON UNIVERSITY
10 Hospital Dr, Saint Peters, MO 63376

Additional Areas of Focus

Dr. Johanns has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Device, Biological, Procedure
Study Drug: Personalized neoantigen DNA vaccine
Study Phase: Phase 1
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Biological, Device
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Disulfiram, Copper Gluconate, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Genetic
Study Phase: Phase 1
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug, Procedure
Study Drugs: CDX-301, CDX-1140
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Belimumab
Study Phase: Phase 1
Mapping Draining Lymph Nodes in CNS Malignancies
Mapping Draining Lymph Nodes in CNS Malignancies
Enrollment Status: Terminated
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drug: Tc-99m tilmanocept
Study Phase: Phase 1
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Radiation, Drug, Procedure
Study Drug: Avelumab
Study Phase: Phase 1
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drug: Tadalafil
Study Phase: Phase 1
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Enrollment Status: Completed
Publish Date: November 24, 2021
Intervention Type: Drug, Radiation, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Biological
Study Phase: Phase 1
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Enrollment Status: Withdrawn
Publish Date: May 25, 2021
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: November 17, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 23 Less Clinical Trials

48 Total Publications

Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis.
Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis.
Journal: Journal of neuro-oncology
Published: March 12, 2025
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. George Ansstas
Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. George Ansstas
Hematology | Oncology

Washington University

10 Barnes W Dr, 
Saint Louis, MO 
 (14.2 miles away)
Languages Spoken:
English
See accepted insurances

George Ansstas is a Hematologist and an Oncologist in Saint Louis, Missouri. Dr. Ansstas is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Astrocytoma, Glioblastoma, Melanoma, Bone Marrow Aspiration, and Tissue Biopsy.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Omar Butt
Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Omar Butt
Hematology | Oncology

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (9.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Omar Butt is a Hematologist and an Oncologist in Saint Louis, Missouri. Dr. Butt is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Tissue Biopsy.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Milan Chheda
Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Milan Chheda
Oncology

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (9.8 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances

Milan Chheda is an Oncologist in Saint Louis, Missouri. Dr. Chheda is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Johanns's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile